Aldosterone Breakthrough During Diovan (Valsartan), Tekturna (Aliskiren), and Combination (Valsartan+Aliskiren) Anti-hypertensive Therapy in Patients With Proteinuric Kidney Disease.

Trial Profile

Aldosterone Breakthrough During Diovan (Valsartan), Tekturna (Aliskiren), and Combination (Valsartan+Aliskiren) Anti-hypertensive Therapy in Patients With Proteinuric Kidney Disease.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 01 Jul 2014

At a glance

  • Drugs Aliskiren (Primary) ; Valsartan (Primary)
  • Indications Hypertension
  • Focus Pharmacodynamics
  • Most Recent Events

    • 16 Apr 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 06 Apr 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 15 Feb 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top